Merck, Neuromed Discontinue N-Type Calcium Channel Blocker For Pain
This article was originally published in The Pink Sheet Daily
Executive Summary
Companies will continue a joint research effort to deliver a “best in class” candidate, Neuromed CEO Gallen tells “The Pink Sheet” DAILY.
You may also be interested in...
Neuromed Deal With Alza Will Accelerate Commercialization Strategy
Neuromed will develop a sales force to launch OROS hydromorphone in the U.S. in 2009 under a collaboration with the J&J subsidiary.
Merck Signs On For Neuromed’s Chronic Pain Agent
Merck could pay up to $450 mil. for the class of oral N-type calcium channel blockers.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.